Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Board and management have taken decisive actions to strengthen leadership and focus clinical priorities, particularly for blarcamesine's development across Alzheimer's, Rett syndrome, and Fragile X syndrome.

• Recent financial results and business updates show regulatory momentum and a disciplined strategy aligned with FDA requirements.

• Company has brought financial reporting current and is working with Nasdaq to regain compliance.

• Forward-looking statements caution that actual results may differ due to various risks and uncertainties.

Voting matters and shareholder proposals

• Six director nominees are proposed for election, including two new nominees, with a call to vote for the slate on the WHITE proxy card.

• A competing slate from PVG is opposed, with concerns about their lack of relevant experience and minimal share ownership.

Board of directors and corporate governance

• The board is described as balanced, with experienced, independent leadership and fresh perspectives.

• The Scientific Advisory Board has been refreshed to focus on Alzheimer's disease expertise.